DrugPatentWatch Database Preview
Litigation Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)
| Docket | Start Trial | Date Filed | 2017-06-26 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Defendant | Referred To | |
| Parties | ACCORD HEALTHCARE INC.; ALKEM LABORATORIES LTD.; AMNEAL PHARMACEUTICALS LLC; AUROBINDO PHARMA U.S.A., INC.; AUROBINDO PHARMA USA LLC; BIOGEN INTERNATIONAL GMBH; BIOGEN MA INC.; CARIBE HOLDINGS (CAYMAN) CO. LTD.; CIPLA LIMITED; CIPLA USA INC.; DBA PURACAP CARIBE; GLENMARK PHARMACEUTICALS INC. USA; GLENMARK PHARMACEUTICALS LIMITED; GRAVITI PHARMACEUTICALS INC.; GRAVITI PHARMACEUTICALS PVT. LTD.; HETERO LABS LIMITED; HETERO LABS LIMITED UNIT-III; HETERO USA INC.; IMPAX LABORATORIES INC.; IMPAX LABORATORIES LLC; LUPIN ATLANTIS HOLDINGS SA; MACLEODS PHARMA USA, INC.; MACLEODS PHARMACEUTICALS LTD.; MSN LABORATORIES PRIVATE LTD.; MSN PHARMACEUTICALS INC.; PHARMATHEN S.A.; PRINSTON PHARMACEUTICAL INC.; PURACAP INTERNATIONAL LLC; S&B PHARMA, INC.; SANDOZ INC.; SAWAI PHARMACEUTICAL CO., LTD.; SAWAI USA INC.; SHILPA MEDICARE LIMITED; SLAYBACK PHARMA INDIA LLP; SLAYBACK PHARMA LLC; SUN PHARMA GLOBAL FZE; TEVA PHARMACEUTICALS USA INC.; TORRENT PHARMA INC.; TORRENT PHARMACEUTICALS LTD.; TWI PHARMACEUTICALS INC.; TWI PHARMACEUTICALS USA INC.; WINDLAS HEALTHCARE PVT. LTD.; ZYDUS PHARMACEUTICALS (USA) INC. | ||
| Patents | 6,509,376; 7,320,999; 7,619,001; 7,803,840; 8,399,514; 8,759,393 | ||
| Attorneys | Aaron F. Barkoff; Adam Wyatt Poff; Alan Tenenbaum; Alejandro Menchaca; Alison M. Hill; Andrew Colin Mayo; Andrew E. Renison; Andy J. Miller; Anne Shea Gaza; Arthur G. Connolly , III; Benjamin J. Schladweiler; Bindu Ann George Palapura; Brian Sodikoff; Christopher B. Ferenc; Christopher M. Bruno; Christopher P. Galligan; David A. Bilson; David Ellis Moore; Dominick T. Gattuso; Don J. Mizerk; Dustin L. Taylor; Emily N. Winfield; Eric J. Fues; Erin M. Forbes; Erin R. Conway; Eve H. Ormerod; Frank D. Rodriguez; Frederick R. Ball; Gary Ji; George C. Lombardi; George J. Barry , III; Huiya Wu; Imron T. Aly; James B. Monroe; James P. Barabas; James S. Green , Jr.; Jeanette M. Roorda; Jeffer Ali; Jing Xia; John C. Phillips , Jr.; John R. McNair; Jonathan B. Turpin; Joseph E. Cwik; Joseph M. Reisman; Jovial Wong; Kelly E. Farnan; Kenton M. Walker; Kevin E. Warner; Li Feng; Loni L. Morrow; Mark Rubinshtein; Matthew M. Holub; Michael J. Gaertner; Michelle A. Herrera; Naomi L. Birbach; Neal C. Belgam; Patrick C. Gallagher; Paul W. Browning; Philip D. Segrest; Philip Y. Braginsky; Pilar Gabrielle Kraman; Rachel P. Waldron; Rajendra A. Chiplunkar; Richard L. Renck; Samantha G. Wilson; Samuel Sherry; Sanya Sukduang; Sara E. Bussiere; Saukshmya Trichi; Scott B. Feder; Shailendra K. Maheshwari; Stamatios Stamoulis; Stephen B. Brauerman; Steven J. Balick; Steven J. Moore; Thomas H. Ehrich; Thomas P. Krzeminski; Timothy F. Peterson; Timothy H. Kratz; Todd S. Werner; Vincent L. Capuano; William A. Rakoczy; William R. Zimmerman; Yun Wei | ||
| Firms | Bayard, P.A.; Connolly Gallagher LLP; Duane Morris, LLP; Greenberg Traurig, the Nemours Building; Heyman Enerio Gattuso & Hirzel LLP; Phillips, Goldman, McLaughlin & Hall, P.A.; Smith, Katzenstein, & Jenkins LLP; Stamoulis & Weinblatt LLC; Young, Conaway, Stargatt & Taylor LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Biogen International GmbH v. Amneal Pharmaceuticals LLC
The small molecule drug covered by the patents cited in this case is Start Trial .
Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | 1 | is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the…regarding the ’376 patent, the ’999 patent, the ’001 patent, the ’840 patent and the ’514 patent, has a substantial…“the ’999 patent”), 7,619,001 (“the ’001 patent”), 7,803,840 (“the ’840 patent”) and 8,399,514 (“the …the ’514 patent”) arising under the patent laws of the United States, Title 35, United States Code, §§ … FIRST COUNT FOR PATENT INFRINGEMENT (’376 PATENT) 23. Biogen realleges | External link to document | |
| 0000-00-00 | 121 | Notice of Service | U.S. Patent No. 6,509,376; and (2) Zydus's Initial Invalidity Contentions Regarding U.S. Patent 6,509,376… 26 June 2017 1:17-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) | External link to document |
| 0000-00-00 | 166 | Stipulation of Dismissal | infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ʼ999 patent”) and 8,399,514…8,399,514 (“the ’514 patent”) (collectively, the “Asserted Patents”): Biogen MA Inc. v. Impax Laboratories, …Stipulation grants no rights to Impax under any patents or other proprietary rights. … 26 June 2017 1:17-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) | External link to document |
| 0000-00-00 | 236 | Opinion - Memorandum Opinion | alleging infringement of U.S. Patent Nos. 6,509,376 ("the ' 376 patent"), 7,320,999 ("the… 514 patent") (collectively, "patents-in-suit" or "asserted patents"). …;the ' 999 patent"), 7,619,001 ("the ' 001 patent"), 7,803 ,840 ("the '…#39; 840 patent"), 8,759,393 ("the ' 393 patent"), and 8,399,514 ("the ' 514…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the | External link to document |
| 0000-00-00 | 292 | Notice of Service | Pharmaceutical Inc.'s Infringement of U.S.Patent No. 8,399,514; (2) Opening Expert Report of Robert O. …Pharmaceutical Inc.'s Infringement of U.S. Patent No. 8,399,514; (3) Opening Expert Report of Daniel R. …Pharmaceuticals Inc.'s Infringement of U.S. Patent No. 8,399,514; (4) Opening Expert Report of Robert O. …Pharmaceuticals Inc.'s Infringement of U.S. Patent No. 8,399,514; (5) Opening Expert Report of Daniel R. …Pharmaceutical Co., Ltd.'s Infringement of U.S. Patent No. 8,399,514; (6) Opening Expert Report of Robert O. | External link to document |
| 2019-11-08 | 326 | Stipulation-General (See Motion List for Stipulation to Extend Time) | -4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the ’514 patent”) (collectively, the “Asserted…Asserted Claims” of the “Asserted Patent”) by submitting, or causing to be submitted, Abbreviated New Drug …WHEREAS claims 5, 7, 14, and 17-20 of the Asserted Patent have not been asserted; WHEREAS, Zydus…(A)(vii)(IV) that, in its opinion, the Asserted Patent is invalid or would not be infringed by the commercial… 26 June 2017 1:17-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
